Burning Rock Biotech - ADR Share Price Today

Burning Rock Q2FY26 Results: Revenue falls 9.3% YoY, in-hospital segment grows

Revenue fell 9.3% YoY to RMB134.7 million, dragged down by a 31.8% drop in pharma services. In-hospital revenue grew 7.4% YoY to RMB67.1 million, offsetting declines in other segments. Net loss widened to RMB18.4 million from RMB9.7 million, driven by higher sales and admin costs. R&D expenses cut by 37.3% to RMB31.2 million amid temporary slowdown in research phases. Multiple NGS kits entered priority review channels under China's CMDE regulatory framework.

Burning Rock CEO buys 73,141 ADSs for US$618.2K

Burning Rock Biotech Limited CEO Yusheng Han acquired 73,141 ADSs for US$618,217.72, increasing his total open-market holdings to 145,874 ADSs worth US$1,976,542.90 over three consecutive post-earnings trading windows.

Burning Rock Biotech Q1 sales fall 14.7% to $15.6M

Burning Rock Biotech reported a net loss per share of $(0.20) for Q1 2026, unchanged from the prior year, as sales fell 14.67% to $15.649 million. Revenue declines were driven by lower performance in central laboratory, in-hospital, and pharma R&D channels.